A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing. In one method, tissue leaflets in assembled bioprosthetic heart valves are preconditioned by simulating actual flow conditions for a predetermined number of cycles, during or after which the valve is exposed to the capping agent.

The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.

A method of preparing biological tissue for use as a component of an implant, in particular as part of a heart valve prosthesis, which can be implanted by catheter. The biological tissue is subjected to a dimensional and structural stabilization step and is dried. For the dimensional and structural stabilization, a combination of a first, polyethylene glycol-containing solution and at least one second, glycerol-containing solution is used.

Provided is a technology that can provide an excellent suppressive effect against adhesion of calculi or calcification in a medical device to be retained within the body. This agent for suppressing calculi adhesion or calcification contains polydopamine and/or a derivative thereof, and is used to form at least an outermost surface of a coating layer of a medical device to be retained within a urinary organ or a circulatory organ.

A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.

Methods for treating a bioprosthetic tissue are described herein. The methods comprise contacting the bioprosthetic tissue with at least one nucleophile and/or at least one electrophile in the presence of a catalytic system comprising at least one or a combination of a fluoride-based salt, a cesium-based salt, a potassium-based salt, a rubidium-based salt, or a carbonate-based salt. The methods may be used to alter functional groups on biological tissue which represent actual and potential calcium binding sites and also processes for cross-linking bioprosthetic tissue. Both processes may be used in conjunction with known fixative techniques, such as glutaraldehyde fixation, or may be used to replace known fixative techniques.

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods that include a cord that is flexible and elongated defining a length. The cord may include a core having a porous surface and a porosity-reducing element on at least a portion of the core.

The present invention is directed to compositions and methods for the prevention or treatment of treatment of heterotopic ossification, vascular calcification, or pathologic calcification.

The present disclosure provides a composite decellularized matrix membrane and use thereof. The composite decellularized matrix membrane prepared by the present disclosure is prepared by wrapping one layer of a polymer membrane with two layers of decellularized matrix membranes. The decellularized matrix membrane is prepared from at least a biomaterial of a porcine small intestine, a porcine bladder, and porcine skin. The polymer membrane is prepared from at least a polymer material of polycaprolactone, polydimethylsiloxane, polyurethane, polylactic acid-glycolic acid, polyvinyl alcohol, and polyhydroxy fatty acid ester. The composite decellularized matrix membrane prepared by the present disclosure can prevent calculi, makes a patient suffer less, recover faster, live better, and cost less, while medical resources are saved, and hope for treatment is also brought for some patients with a contraindication to an in-situ ileal neobladder surgery.

A composite ultra-thin coating film with hypersensitivity inflammatory reaction inhibition and antibacterial activity, an implant comprising the same, and a method for preparing the same are described. The composite ultra-thin coating film can be applied to medical silicone-based polymers and exhibits excellent antibacterial activity and inhibits deformed cell proliferation so that hypertrophic tissue is not formed and there is no cytotoxicity.